Accelerating new treatments for global infectious diseases
Mission – What we do
To synthesize the extraordinary and diverse scientific expertise of CAMM investigators to transform the therapeutics development process, accelerating cures for microbial diseases of public health importance.
Vision – What we will achieve
A new era in which molecular measures of microbial cellular processes guide therapeutics development, enabling faster, smarter, more accurate selection of improved drugs and vaccines that save human lives.
Purpose – Why we do it
To innovate solutions for a key roadblock that holds back therapeutics development: the need for improved measures of therapeutic efficacy.
CAMM receives $980,000 award from CRDF Global for RS ratio for measuring immune efficacy and bacterial physiology in TB April 2023
>> CAMM releases manuscript preprint describing M tuberculosis phenotypes within lung microenvironments
CAMM releases manuscript preprint describing M tuberculosis phenotypes within lung microenvironments with distinct treatment responses March 2023 https://www.biorxiv.org/content/10.1101/2023.02.03.527062v1
CAMM partners with Boston BioProducts, Inc for cGMP manufacturing of RS ratio materials March 2023